**Supplementary table 1. Clinical characteristics of PCR+ and PCR- asymptomatic COVID-19 patients and of PCR+ and PCR- symptomatic COVID-19 patients**. PCR- pateins were considered to have COVID-19 if they developed anti-SARS-VoV-2 antibodies. P value for the comparison of PCR positive vs PCR negative patients within each symptoms category as well as for the full asymptomatic vs symptomatic groups.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Asymptomatic** | **p value** | **Symptomatic** | **p value** | **p Asymptomatic vs Symptomatic** |
|  | **PCR+** | **PCR-** | **PCR+** | **PCR-** |
| N | 5 | 7 |  | 33 | 5 |  |  |
| Age (years) | 65.6±10.7 | 68.4±14.1 | n.s | 73.7±11.8 | 67±15.6 | n.s. | n.s. |
| Female (%) | 2 (40%) | 3 (42,9%) |  | 10 (30.3%) | 1 (20%) |  |  |
| BMI (kg/m2) | 23.6±4.07 | 25.5±4.1 | n.s | 24.5±4.88 | 25.8±3.75 | 0.45 | n.s. |
| ACEIs, n (%) | 0 (0%) | 0 (0%) | - | 9 (27.2%) | 1 (20%) | n.s | 0.047 |
| ARBs, n (%) | 2 (40%) | 1 (14.2%) | n.s | 3 (9.1%) | 0 (0%) | n.s | n.s. |
| 25 (OH) Vitamin D (ng/ml) | 17.4±6.67 | 21.7±10.6 | n.s | 23.3±18.1 | 22.6±13.8 | 0.829 | n.s. |
| Lymphocyte count 3 mo ago (/µl) | 1120±396 | NA |  | 1309±621 | NA |  |  |
| Positive anti-SARS-CoV-2 antibodies, n (%) | 5 (100%) | 7 (100%) | n.s | 24 (72.7%) | 5 (100%) | n.s | n.s |
| **Clinical manifestations** |  |
| Fever, n (%) | 0 (0%) | 0 (0%) | - | 12 (36.4%) | 4 (80%) | n.s | - |
| Dyspnea, n (%) | 0 (0%) | 0 (0%) | - | 4 (12.1%) | 0 (0%) | n.s | - |
| Pneumonia, n (%) | 1 (20%) | 0 (0%) | - | 23 (69.7%) | 3 (60%) | n.s | - |
| Oxygen saturation (%) | 97.3±2.36 | 97±NaN | n.s | 92.8±4.42 | 95.5±4.12 | n.s. | 0.024 |
| **Labs** |  |
| Hemoglobin (g/dL) | 12.2±1.48 | 11.4±1.69 | n.s | 11.2±1.43 | 11±2.53 | n.s | n.s |
| Lymphocyte count at admission (/µl) | 1460±643 | 1143±294 | n.s | 661±343 | 633±339 | n.s | **< .001\*** |
| D-Dimer (µg/l) | 903±480 | 1726±1107 | n.s | 1580±1373 | 2273±2079 | n.s | n.s |
| Ferritin (ng/mL) | 918±888 | 616±500 | n.s | 1280±1513 | 740±915 | n.s | n.s |
| Troponin I (ng/mL) | 0.011±0.001 | 0.039±0.031 | n.s | 1.47±6.94 | 0.039±0.039 | n.s | **0.044\*** |
| KL6 (U/mL) | - | - | - | 308±107 | 373±316 | n.s | - |
| IL6 (pg/mL) | 8.63±3.5 | 13.5±11.3 | n.s | 50.3±70 | 64.9±93.2 | n.s | **0.03\*** |
| **Outcomes** |  |  |
| Hospitalization, n (%) | 0 (0%) | 0 (0%) | - | 21 (63.6%) | 4 (80%) | n.s | **< .001\*** |
| Death, n (%) | 0 (0%) | 0 (0%) | - | 7 (21.2%) | 0 (0%) | n.s | n.s |

NA: not available; \* For categorical data, the number of positive events observed, and the Fisher's exact test values are shown.